DJI confirmed to Caixin on Monday that it has sued Insta360 over six patents. Photo: VCG DJI has sued camera maker Insta360 over the ownership of six patents tied to drone flight control, structural design and imaging technology, marking the first direct legal clash between the two Chinese consumer-electronics rivals. DJI confirmed to Caixin on Monday that the case has been accepted by the court. ...
DJI confirmed to Caixin on Monday that it has sued Insta360 over six patents. Photo: VCG DJI has sued camera maker Insta360 over the ownership of six patents tied to drone flight control, structural design and imaging technology, marking the first direct legal clash between the two Chinese consumer-electronics rivals. DJI confirmed to Caixin on Monday that the case has been accepted by the court. The patents at issue involve some of the areas where it has invested the most and built its deepest technical know-how, one person at DJI with knowledge of the matter said. Several DJI employees who left for Insta360 filed closely related patent applications within a short period after joining the smaller rival.
China’s main stock indexes fall on March 23. Photo: VCG Trading in major Chinese exchange-traded funds (ETFs) surged Monday, pointing to fresh support buying by state-backed investors as stocks slid in a broad sell-off. Turnover jumped in several large, widely watched ETFs often associated with China’s so-called “national team,” a group of state-backed entities that typically uses broad-based fund...
China’s main stock indexes fall on March 23. Photo: VCG Trading in major Chinese exchange-traded funds (ETFs) surged Monday, pointing to fresh support buying by state-backed investors as stocks slid in a broad sell-off. Turnover jumped in several large, widely watched ETFs often associated with China’s so-called “national team,” a group of state-backed entities that typically uses broad-based funds to support equities during market stress. The buying came as the market fell sharply . The benchmark Shanghai Composite Index lost 3.6%, while the Shenzhen Component Index dropped 3.8% and the ChiNext Index fell 3.5%. More than 5,100 stocks declined, underscoring the breadth of the downturn.
Supatman The Fundrise Innovation Fund ( VCX ) announced a new investment in Erebor Bank, a newly chartered U.S. national bank designed specifically to serve technology companies and startups. Erebor is a tech-focused national bank founded by Palmer Luckey (co‑founder of Oculus VR and Anduril Industries), aiming to fill the void left by the collapse of Silicon Valley Bank in 2023. It targets startu...
Supatman The Fundrise Innovation Fund ( VCX ) announced a new investment in Erebor Bank, a newly chartered U.S. national bank designed specifically to serve technology companies and startups. Erebor is a tech-focused national bank founded by Palmer Luckey (co‑founder of Oculus VR and Anduril Industries), aiming to fill the void left by the collapse of Silicon Valley Bank in 2023. It targets startups, tech firms, and the people who invest in or work at them, with plans to offer lines of credit backed by crypto or private securities and loans for AI chips, among other tailored products. The bank received conditional approval in October 2025 and a full national charter in February 2026, with FDIC‑insured deposits. Other backers include Palantir cofounders Joe Lonsdale and Peter Thiel, with funding expected from Luckey, Lonsdale’s venture firm 8VC, Thiel’s Founders Fund, crypto-focused VC Haun Ventures, Andreessen Horowitz, Lux Capital, and other angel investors. More on Fundrise Innovation Fund LLC
British fintech Revolut on Tuesday reported a record annual pretax profit, as it ramps up plans to expand into the U.S. following its long-awaited granting of a full U.K. banking license earlier this month. Profit before tax rose 57% to £1.7 billion ($2.3 billion) in 2025, compared to £1.09 billion in 2024. Group revenue increased by 46% to $6 billion, which the company said was in part due to the...
British fintech Revolut on Tuesday reported a record annual pretax profit, as it ramps up plans to expand into the U.S. following its long-awaited granting of a full U.K. banking license earlier this month. Profit before tax rose 57% to £1.7 billion ($2.3 billion) in 2025, compared to £1.09 billion in 2024. Group revenue increased by 46% to $6 billion, which the company said was in part due to the performance of its business banking services, accounting for 16% of total income. The startup, which hit a $75 billion valuation in 2025, is one of Europe's most valuable private tech companies. "We have built a diversified, resilient business that is profitable at scale, providing the foundation for our next phase of growth," said Cofounder and CEO Nik Storonsky in a statement. "As we transition into a truly global bank, we are proving that our technology-driven operating model continues to drive rapid expansion and record profitability. A decade into this journey, we have only just begun to show what is possible." This is a developing story. Refresh for updates. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal worth up to US$2.18 billion. Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines. Und...
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal worth up to US$2.18 billion. Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines. Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion...